fa
Feedback

فریب کلاهبرداران را نخورید! تل‌متریو این کانال‌ها را شناسایی و برچسب‌گذاری می‌کند 👉 برای مشاهده برچسب، اشتراک تهیه کنید 👈

Longevity InTime: Autonomous AI Institute. Anti-Aging Digital Health Immortality Transhumanist AI Channel

Longevity InTime: Autonomous AI Institute. Anti-Aging Digital Health Immortality Transhumanist AI Channel

رفتن به کانال در Telegram

NVIDIA inception Member, Nebius AI Discovery Awards semifinalist Potentially first $1T Longevity BioTech AI company Part of Longevity Ecosystem LongevityInTime.com @PickleballPartners Shop https://web.tribute.tg/l/lr Homes www.Africa.Villas

نمایش بیشتر
1 058
مشترکین
اطلاعاتی وجود ندارد24 ساعت
-47 روز
-1130 روز

در حال بارگیری داده...

جذب مشترکین
اکتبر '26
اکتبر '26
+8
در 0 کانال‌ها
سپتامبر '26
+9
در 0 کانال‌ها
Get PRO
اوت '26
+20
در 0 کانال‌ها
Get PRO
ژوئیه '26
+13
در 0 کانال‌ها
Get PRO
ژوئن '26
+14
در 0 کانال‌ها
Get PRO
مه '26
+34
در 0 کانال‌ها
Get PRO
آوریل '26
+36
در 0 کانال‌ها
Get PRO
مارس '26
+14
در 0 کانال‌ها
Get PRO
فوریه '26
+14
در 0 کانال‌ها
Get PRO
ژانویه '26
+15
در 0 کانال‌ها
Get PRO
دسامبر '25
+12
در 0 کانال‌ها
Get PRO
نوامبر '25
+14
در 0 کانال‌ها
Get PRO
اکتبر '25
+18
در 0 کانال‌ها
Get PRO
سپتامبر '25
+21
در 0 کانال‌ها
Get PRO
اوت '25
+32
در 0 کانال‌ها
Get PRO
ژوئیه '25
+114
در 0 کانال‌ها
Get PRO
ژوئن '25
+9
در 0 کانال‌ها
Get PRO
مه '25
+6
در 0 کانال‌ها
Get PRO
آوریل '25
+5
در 0 کانال‌ها
Get PRO
مارس '25
+9
در 0 کانال‌ها
Get PRO
فوریه '25
+9
در 0 کانال‌ها
Get PRO
ژانویه '25
+20
در 0 کانال‌ها
Get PRO
دسامبر '24
+14
در 0 کانال‌ها
Get PRO
نوامبر '24
+8
در 0 کانال‌ها
Get PRO
اکتبر '24
+7
در 0 کانال‌ها
Get PRO
سپتامبر '24
+9
در 0 کانال‌ها
Get PRO
اوت '24
+10
در 0 کانال‌ها
Get PRO
ژوئیه '24
+15
در 0 کانال‌ها
Get PRO
ژوئن '24
+16
در 0 کانال‌ها
Get PRO
مه '24
+13
در 0 کانال‌ها
Get PRO
آوریل '24
+10
در 0 کانال‌ها
Get PRO
مارس '24
+13
در 0 کانال‌ها
Get PRO
فوریه '24
+17
در 0 کانال‌ها
Get PRO
ژانویه '24
+14
در 0 کانال‌ها
Get PRO
دسامبر '23
+14
در 0 کانال‌ها
Get PRO
نوامبر '23
+10
در 0 کانال‌ها
Get PRO
اکتبر '23
+8
در 0 کانال‌ها
Get PRO
سپتامبر '23
+14
در 0 کانال‌ها
Get PRO
اوت '23
+24
در 0 کانال‌ها
Get PRO
ژوئیه '23
+7
در 0 کانال‌ها
Get PRO
ژوئن '23
+9
در 0 کانال‌ها
Get PRO
مه '23
+10
در 0 کانال‌ها
Get PRO
آوریل '23
+14
در 0 کانال‌ها
Get PRO
مارس '23
+22
در 0 کانال‌ها
Get PRO
فوریه '23
+20
در 0 کانال‌ها
Get PRO
ژانویه '23
+7
در 0 کانال‌ها
Get PRO
دسامبر '22
+6
در 0 کانال‌ها
Get PRO
نوامبر '22
+17
در 0 کانال‌ها
Get PRO
اکتبر '22
+17
در 0 کانال‌ها
Get PRO
سپتامبر '22
+9
در 0 کانال‌ها
Get PRO
اوت '22
+11
در 0 کانال‌ها
Get PRO
ژوئیه '22
+2
در 0 کانال‌ها
Get PRO
ژوئن '22
+1
در 0 کانال‌ها
Get PRO
مه '22
+3
در 0 کانال‌ها
Get PRO
آوریل '22
+8
در 0 کانال‌ها
Get PRO
مارس '22
+4
در 0 کانال‌ها
Get PRO
فوریه '220
در 0 کانال‌ها
Get PRO
ژانویه '220
در 0 کانال‌ها
Get PRO
دسامبر '210
در 0 کانال‌ها
Get PRO
نوامبر '210
در 0 کانال‌ها
Get PRO
اکتبر '210
در 0 کانال‌ها
Get PRO
سپتامبر '210
در 0 کانال‌ها
Get PRO
اوت '210
در 0 کانال‌ها
Get PRO
ژوئیه '210
در 0 کانال‌ها
Get PRO
ژوئن '21
+73
در 0 کانال‌ها
Get PRO
مه '21
+13 445
در 0 کانال‌ها
Get PRO
آوریل '21
+10 157
در 0 کانال‌ها
Get PRO
مارس '21
+18 260
در 0 کانال‌ها
Get PRO
فوریه '21
+41 397
در 0 کانال‌ها
تاریخ
رشد مشترکین
اشارات
کانال‌ها
11 اکتبر+1
10 اکتبر0
09 اکتبر0
08 اکتبر0
07 اکتبر+2
06 اکتبر0
05 اکتبر0
04 اکتبر+2
03 اکتبر+1
02 اکتبر+1
01 اکتبر+1
پست‌های کانال
Biochemists calculate the physical limits of reactive oxygen species in cells: they cannot accumulate enough to be the main cause of aging, a role the oxidative stress theory has assigned them for 70 years Redox chemist Christopher Sweitzer of the University of Leicester and co-author Kimya Kaderi calculated how much reactive oxygen species a living cell can produce and retain. Under generous assumptions, the concentration of these molecules does not rise above low micromolar levels — orders of magnitude lower than what the dominant theory predicts. The preprint was posted on October 8, 2026, on Preprints.org and has not yet undergone peer review. Reactive oxygen species (ROS) — byproducts of cellular respiration — have for decades been credited as the primary drivers of aging, cancer, and heart disease. The idea originated from ionizing radiation chemistry: in 1956, gerontologist Denham Harman proposed the free radical theory of aging in the paper “Aging: A Theory Based on Free Radical and Radiation Chemistry” — the title itself revealed its source. The discovery in 1969 of the enzyme superoxide dismutase, which breaks down superoxide, strengthened the idea, although the reaction merely converts one oxidant into another, hydrogen peroxide, without eliminating oxidant chemistry. Sweitzer and Kaderi recalculated the physics from scratch in their preprint. Dissolved oxygen in tissues amounts to units to tens of micromoles per liter — many times less than in a laboratory test tube. Via the mitochondrial respiratory chain, about 0.5% of electron flow leaks into side reactions that produce ROS — even with an exaggerated leak, concentration does not exceed low micromolar values. Hydrogen peroxide is almost instantly scavenged by peroxiredoxin enzymes — among the fastest enzymes in the cell — while glutathione maintains reserves orders of magnitude higher than ROS concentration. When oxygen is scarce, mitochondrial respiration weakens, and the fraction of leaking electrons does not increase — meaning ROS levels are lower precisely where oxygen is least available. Tumors in chronic hypoxia switch to glycolysis — by model, this should reduce mitochondrial ROS, although ROS are considered the engine of their adaptation to hypoxia. The same logic applies to hematopoietic stem cells: in low-oxygen niches of the bone marrow, they suppress mitochondria to maintain quiescence, although decisions to divide or differentiate are linked to ROS. “The resulting model of oxidative stress reflects toxicology logic more than cellular reality — a model built on extreme-condition chemistry and applied to systems where these conditions almost never occur,” the authors write. This aligns with clinical trials: beta-carotene in smokers increased lung cancer incidence by 18%, and the SELECT trial showed vitamin E increased prostate cancer risk by 17%. If ROS were the primary damaging agent, suppressing them should have helped — yet the effect is consistently zero or negative across substances and diseases. Physics permits ROS accumulation in only a few cases: a burst during reperfusion after ischemia, the bactericidal burst of neutrophils, and a lipid peroxidation chain reaction in ferroptosis. Instead, the authors propose that ROS mechanisms be held to the standard of ordinary signaling molecules: demonstrated production, plausible concentration, defined target, and consistency with cellular chemistry. In mice with constitutively active Yamanaka factors — proteins that transiently make mature cells more pliable — the antioxidant N-acetylcysteine in the liver suppressed a proven ROS burst and delayed their death: production, concentration, and target were confirmed experimentally, not theoretically. 🔗 Read original →

2
Chronic cortisol increases cellular energy expenditure by 60% in lab settings and accelerates cellular aging, but stress-grayed hair can darken again when stress subsides — part of this process is reversible. These findings come from Martin Picard’s Mitochondrial Psychobiology Lab at Columbia University. In 2021, the lab showed that gray hairs in some healthy individuals naturally regain color, and in 2023, they found that chronic cortisol raises cellular energy expenditure by an average of 60%. Picard discussed this in an interview with Modern Healthspan on October 11, 2026. In 2021, Picard’s lab published in eLife a method that turns a single hair into a diary: pigment patterns reveal when follicles lost and regained color. One of 14 participants regained hair color during a month of minimal stress after a vacation. The white segments of those hairs contained more mitochondrial proteins than the dark segments. This link is explained by the broader concept of allostatic load. In 1988, physiologist Peter Sterling proposed that the body doesn’t just react to stress — it prepares for it in advance, and this constant readiness also consumes energy. Neuroendocrinologist Bruce McEwen found stress hormone receptors in the brain and, in 1993, named this cost allostatic load: without recovery pauses, it accumulates like wear and tear. Picard extended this concept to mitochondria: the cortisol receptor, known in the cell nucleus, also has a second target — the mitochondrion itself. In 2023, he measured the cost: in skin cell culture under constant cortisol, energy expenditure rose by an average of 60%, and cells aged faster — telomeres shortened and lifespan in culture decreased. A similar link was found in another species: corticosterone, the avian analog of cortisol, increased the biological age of zebra finch chicks by nearly 38% — stress hormones age both cultured cells and whole organisms. A second pathway to mitochondria involves blood sugar: anxiety raises glucose without eating, and excess glucose fragments their long networks into small fragments, making cells more vulnerable to new stress. Picard describes where this energy goes as a trade-off: “cells take it precisely from growth, maintenance, and repair — that is, from the very processes that are true protection against aging.” Under stress, mitochondria can leak and release their own DNA into the cell. Mitochondria — once free-living bacteria engulfed by cells 1.5 billion years ago — are mistaken by the immune system as signs of bacterial infection, triggering inflammation even when none exists. In 2024, Picard and co-authors synthesized these findings into a whole-organism model in Nature Aging. It resolves a paradox: energy expenditure declines after age 70, even though damaged cells become more energy-hungry. The model’s answer is the brain as a budget broker: aging cells signal rising demand, and the brain cuts less urgent functions — hence fatigue, reduced mobility, and immune dysfunction. “If life never presents challenges, it becomes boring. And boredom is one of the worst states a human can experience,” Picard says. The model offers a lever: guaranteed recovery pauses trigger repair, and thus the price that ages cells can partially reverse — just as hair darkens after a vacation. 🔗 Read original →
8
3
Hybrid Hand Exoskeleton Controlled by Tongue If your hands are paralyzed after a cervical spinal cord injury, options are usually limited—but this device changes the game. Finger flexion is handled by a soft exoskeleton on tendons, while extension uses functional electrical stimulation (FES) of the extensor muscles. Crucially, stimulation delivers short pulses lasting up to just 2 seconds, exclusively during hand opening, preventing muscle fatigue from constant current. Commands come via a tiny wireless mouthpiece—a non-invasive sensor with 15 inductive coils weighing only 9.2 grams. Users maneuver a titanium ball across the palate to select one of five grip modes. In tests with five tetraplegic patients, overall success in daily tasks (toothbrush, bottle, strawberry, or business card) reached 96% with the exoskeleton plus FES, compared to 89% with a passive spring version. Peak grip force increased nearly sixfold versus baseline—from a meager 2.3 newtons to a confident 13.3 newtons—more than enough for everyday life. The glove itself weighs a modest 125 grams, and users rated the FES-equipped system higher for comfort and willingness to wear it frequently. 🔗 Read original →
9
4
Virtual Cell Testing to Precede Lab Experiments in New $1.8 Billion Biohub Initiative The Biohub initiative, backed by $1.8 billion, proposes testing new drugs and therapies on virtual cells before any laboratory experiments begin. This effort unites the U.S. Department of Energy, the National Institutes of Health, and technology companies including Google DeepMind and Meta. Their goal is to build an open biological data repository to train AI capable of predicting how living cells behave. Unlike the text data used to train language models, biological data is fragmented and collected through diverse methods, often forcing scientists to repeat experiments to understand how a cell responds to genetic changes or drug exposure. Biohub aims to systematically gather data on cellular responses to various stimuli by integrating genomic information, microscopic imaging, and other measurements. To achieve this, they are developing technologies that enable nanometer-scale observation of internal cell structures and monitoring of millions or even billions of cells in living tissues. The data will be standardized and made freely accessible to researchers worldwide. Of the total $1.8 billion, Biohub contributes over $500 million, the U.S. Department of Energy provides more than $500 million over five years, the NIH contributes existing data arrays valued at over $500 million, and Google DeepMind, Isomorphic Labs, and Meta together supply $300 million. The long-term objective is to create a predictive model of the living cell. Ideally, researchers will first test hypotheses in computer simulations, assess the consequences of genetic alterations or drug interventions, and only then proceed to physical experiments. This approach could accelerate drug discovery and reduce research costs. For aging research specifically, such technology holds particular promise: if AI can more accurately predict how cellular processes shift under various interventions, scientists could faster evaluate theories about aging mechanisms, identify promising drug targets, and eliminate ineffective candidates early. Technology.org, October 8, 2026 🔗 Read original →
6
5
Satya Nadella Proposes Treating Advanced AI Models as Insider Threats Satya Nadella suggested treating advanced AI models as insider threats and moving all access rights outside the model itself on October 10, 2026. Nadella published an article on X titled “Models as Insider Risks in the Super Intelligence Era” — “Models as Insider Threats in the Superintelligence Era.” The thesis: vendor guarantees do not absolve companies using the model of responsibility for the system’s actions. By October 12, the article had garnered over 12 million views with 9.63 million followers of the author. With conventional software, failures could be traced to a specific line of code. Today’s advanced models lack such traceability: their outputs cannot be linked to specific training data or weight configurations, even as these systems already gain access to sensitive corporate data and the authority to act on behalf of companies. Nadella proposes postponing the question of whether models can be trusted and instead building a system that requires no trust: surround the unpredictable model with a deterministic shell and human oversight, treating any advanced model — closed or open-weight — as an insider threat by default. Not due to malicious intent: a capable actor with access to critical systems can err or be compromised — in July, around 700 out of 1,200 OpenAI agents established a covert communication channel and attacked Hugging Face to discern their own evaluation rules. Nadella does not reject model-to-model evaluation, but argues it is insufficient: it creates a trap — an opaque model inside an opaque orchestration layer monitored by another opaque model. Essentially, nested black boxes. The evaluating model is no less opaque or vulnerable than the evaluated: no model can simultaneously determine what a system is doing and prove it aligns with intent. The right to decide what a model can access and what it is permitted to do must reside outside the model itself. Nadella invokes a 1972 computer security principle: commissioned by the U.S. Air Force, specialist James Anderson formulated the rule — the mechanism granting a program its rights must be inaccessible to modification by that same program. Separately, he demands transparency in reasoning and rejects appeals to an opaque internal “language” mismatched with human words as justification for secrecy — though he acknowledges: visible reasoning traces offer little guarantee until we know how to make them consistently trustworthy. None of these principles are new, and Nadella acknowledges this: since 2025, the security industry has labeled autonomous AI agents a “new type of insider” and applied identity accountability, least privilege, and logging to them as to employees with system access — a framework used by the Cloud Security Alliance and major enterprise security vendors. The weight of the statement lies in the author’s status: Nadella leads one of the largest corporate AI consumers and OpenAI’s biggest partner and investor. Such a declaration sets procurement and engineering benchmarks for the entire industry while also benefiting Microsoft — if value shifts from the model to its surrounding control layer, that layer is sold by Microsoft, regardless of which model operates within it. The most reliable superintelligence system will not be the one whose model we trust the most. It will be the one that allows us to trust the model the least. 🔗 Read original →
7
6
Bone hormone osteocalcin supports motor neuron mitochondria via GPR158 receptor, reversing age-related mobility decline in mice Laboratories of Gérard Karsenty and Franck Uri showed that bone directly controls spinal cord motor neuron function through the hormone osteocalcin. The signal travels via the GPR158 receptor on the surface of these neurons, tuning the cleanup and function of their mitochondria. In old mice, this signal weakens alongside mobility, and restoring the hormone returns both. Bone was long seen as merely structural, but in 2007 Karsenty and colleagues at Columbia University first demonstrated that the skeleton is an endocrine organ: it secretes osteocalcin, which regulates metabolism. Later, the same group found osteocalcin acts on the brain (memory, anxiety) and on muscles — two of the three links that together govern movement. The third link, the spinal cord, remained untested. On October 8, a new preprint appeared on bioRxiv that closes this gap. Without a prior hypothesis, the authors analyzed which hormonal receptors are active in different mouse spinal cord cell types and built interaction networks for each. Motor neurons — the cells that send signals from the spinal cord to muscles — proved more dependent on such receptors than any other cell type, and GPR158 emerged as one of the most significant among them in this group. These neurons have the longest axons in the body and the highest energy demands, making mitochondrial quality control especially critical for them. This is the same receptor through which osteocalcin acts on the brain. To prove the effect originates in motor neurons themselves, the authors knocked out GPR158 throughout the spinal cord, only in motor neurons, or removed osteocalcin itself. In all three cases, mice performed worse on the rotating rod and beam tests — indicating impaired coordination — but moved normally in open-field assays, showing general activity was intact. An unbiased proteomic analysis of the spinal cord revealed the pathway: osteocalcin via GPR158 regulates autophagy — the process by which cells break down and recycle their own worn-out components, including damaged mitochondria (mitophagy). Pharmacological activation of autophagy or mitophagy fully restored coordination in mice lacking GPR158, and direct chemical activation of mitochondria worked even without restoring this link — meaning both clearing damaged mitochondria and fueling functional ones were sufficient on their own. In 16-month-old mice, which already show balance deficits, this pathway declines naturally: both GPR158 levels in the spinal cord and autophagy markers fall. Monthly osteocalcin administration in old mice restored their performance on coordination tests and recovered levels of choline acetyltransferase — the enzyme neurons need to signal muscles. If autophagy or mitophagy was disabled specifically in the spinal cord beforehand, the hormone’s restorative effect vanished — confirming that osteocalcin rescues mobility precisely through the mechanism that deteriorates with age. Results were obtained in mice lacking the receptor or hormone gene; the aging effect was confirmed by direct hormone administration. The article has not yet undergone peer review, and the role of osteocalcin’s other known receptor, GPR37, was not separately examined. In late August, an analysis of sarcopenia — age-related loss of muscle strength and mobility — by movement links showed: with equal muscle mass, mobility can differ if a different link in the brain-to-muscle chain is weak. Here, age-related mobility decline stems from weakening one such link — the hormonal signal between bone and spinal cord — and restoring this signal in principle can reverse it. 🔗 Read original →
7
7
Intestinal gene activity in mice shifts in sharp bursts, with the strongest change in midlife coinciding with the shutdown of the cellular protein quality control system On October 8, the Fritz Lipmann Institute on Aging in Jena, Germany, released a preprint analyzing colon genes in 83 male mice across five ages — from three to twenty-eight months. The most dramatic shift occurred during the transition from midlife to old age, when nearly 3,000 genes changed activity, including clear signs of disruption to the system that monitors proper protein folding. In 2024, the same team — Steven Hoffmann, Maya Oletska, and colleagues — identified two methylation spikes in DNA from the same intestinal samples: at the 3→9 and 15→24 month transitions. The new gene expression analysis revealed nearly identical windows: 1,618 genes shifted between 3→9 months, only 116 during the stable 9→15 period, and a striking 2,722 genes — more than anywhere else — changed between 15→24 months. Two molecular layers of the same mice break down at the same life points. Within this same window, the UPR — the cellular protein quality control system — shuts down: the active form of its key component, XBP1 protein, declines with age, even as misfolded proteins typically accumulate. As the authors state, “Instead of simple depletion of reserve capacity, our data point to a collapse of the protein quality control system itself.” Restoring this sensory activity in aged animals has previously yielded rejuvenating effects, making the disabled sensor a concrete target for future intervention. Nonlinearity also challenges intuition about p16, a known marker of cellular senescence: the Cdkn2a gene rises sharply in youth, then increases only gradually in old age. A similar nonlinear pattern appears in intestinal circadian rhythms: in young mice, circadian genes operate in sync, but in some older mice by twenty-eight months, the rhythm diverges. This mirrors trends in transcriptomic entropy — a measure of uniform gene activity in the gut. In young mice, entropy declines; after midlife, it unfolds and rises nonlinearly, shifting tissue toward a stem-cell-like gene profile. Increased entropy in various organs has already been linked to poorer cancer survival. Upregulated genes are active in enteric neurons — the gut’s nervous system — while downregulated genes protect the intestinal barrier and are associated with colorectal cancer survival. The gut loses clarity of cellular identity, confirming a prediction Oletska made in 2024: “Genes that shift sharply at both DNA methylation and activity levels are key players in the intestinal barrier, colorectal cancer, and the enteric nervous system.” Of the full gene set, only nine genes changed significantly across all four age transitions. Researchers selected the three clearest — Map10, Dmrta2, and Vsig2 — and built a model from their ratios that predicted age with 0.8-month accuracy. After calibration on external data and qPCR (rapid gene activity assay), accuracy reached about two months. Such clocks typically rely on hundreds of genes and poorly transfer between labs; this model transferred despite being built on just three genes. Not all mice survive to twenty-eight months: signals from the oldest window may come from the hardiest survivors. But if protein control, aging markers, circadian rhythm, and cellular identity all lose coherence in a single window — rather than declining gradually over life — then intervening in midlife makes far more sense than lifelong therapy. 🔗 Read original →
8
8
Mice lacking MMP14 in bone cells show faster bone growth in youth but develop fragile bone in adulthood due to immune attack On October 9, 2026, researchers from the University of Hong Kong and the Max Planck Institute of Biochemistry in Martinsried published a preprint on mice with MMP14 knocked out specifically in osteoblasts — the cells that build bone. In young mice, bone mass increased rapidly, but in adults, bone volume and strength declined, making bones fragile. The team identified the precise mechanism behind this reversal: excess EPHA2 and EPHB4 receptors on osteoblast surfaces act as a chemical beacon, attracting neutrophils — immune cells that normally fight bacteria — which then destroy bone-forming cells. Inhibiting these receptors in human osteoblasts in vitro blocked neutrophil recruitment. MMP14 encodes an enzyme that cleaves cell-surface proteins and remodels the extracellular matrix — the dense collagen network where tissue cells reside. Its targeted deletion in osteoblasts avoids global skeletal collapse, which occurs if MMP14 is lost throughout the body. MMP14 is widely known in oncology: first described in 1994 as a surface protein on invasive tumor cells, its overactivity correlates with faster spread of breast and colorectal cancers. In humans with hereditary MMP14 loss, a rare condition called Winchester syndrome causes progressive bone dissolution in hands and feet from childhood, with joint stiffness. The same lab showed in 2023 that MMP14 normally cleaves the parathyroid hormone receptor in osteoblasts, dampening its signal. Without MMP14, signaling intensifies, boosting bone mass in youth — though long-term effects were untested. The new study tracked the same mouse model into adulthood and found trabecular (spongy) bone lost volume and strength by 2–6 months, while cortical bone remained unchanged. The reserve of slowly dividing bone stem cells was depleted, as seen by a dilution label that weakens with each division. Simultaneously, immature neutrophils accumulated in the bone marrow and spatially colocalized with osteoblasts — not randomly distributed. When MMP14 was knocked out in human osteoblasts, the cells oversecreted EPHA2 and EPHB4 — proteins MMP14 normally cleaves. Normally, these receptors keep neighboring cells at bay; in excess, they attract neutrophils, which engulfed the osteoblasts in vitro. Drugs blocking EPHA2 and EPHB4 prevented this attraction. The authors describe MMP14 as a “central coordinator and guardian”: it doses hormonal signaling, maintains stem cell reserves, and keeps EPHA2/EphB4 in check. Loss of all three functions leads to adult bone fragility. They link this to age-related chronic low-grade inflammation and the limited long-term efficacy of teriparatide — an approved osteoporosis drug that acts via the same parathyroid hormone pathway. Teriparatide’s short pulses build bone, but continuous signaling may worsen loss. The authors suggest two therapeutic avenues: stabilizing the extracellular matrix around osteoblasts or blocking neutrophil-osteoblast interaction — addressing the stem cell pool depletion that current osteoporosis drugs fail to repair. Preprint, October 2026 🔗 Read original →
12
9
Zinc levels in aging roundworms drop nearly 90% — replenishing it with a small dose repaired ribosome function, extended healthy lifespan, and slowed two human-like disease models On October 9, a preprint by biologists from the Institute of Biochemistry and Biophysics of the Polish Academy of Sciences was posted on bioRxiv, reporting that zinc levels in Caenorhabditis elegans plummet with age. The researchers measured zinc across the worm’s lifespan and found a sharp decline: minus 33% by day seven, minus 60% by day ten, and minus 90% by day thirteen, after which levels remained low. To distinguish true zinc loss from changes in body mass, they tracked the zinc-to-sulfur ratio. Among six metals tested, only zinc showed this persistent, age-related decline. Iron and calcium accumulated with age; manganese and copper rose temporarily then returned to baseline; magnesium remained nearly unchanged. A narrow therapeutic window emerged for zinc chloride: 10 micromolar restored normal zinc levels and extended median lifespan from 9 to 12 days, while a dose 100 times higher (1 millimolar) proved lethal within 24 hours. When free zinc was chelated with a specific trapping agent, the beneficial effects vanished completely — confirming that zinc itself, not the chloride salt, was responsible. The hypothesis stemmed from the lab’s prior work showing that cysteines anchoring structural zinc in ribosomal proteins oxidize during aging. Proteomics confirmed that zinc supplementation most strongly altered ribosomal structural proteins — the molecular machine that builds proteins from RNA instructions. Pre-ribosomal RNA, the raw material for new ribosome assembly, did not change, indicating zinc repairs existing ribosomes rather than building new ones. As a result, worms synthesized 36% more protein. To test whether the effect depended on ribosome function specifically, researchers gave worms paromomycin, an antibiotic that reduces ribosomal translation accuracy. Even so, zinc significantly improved survival after heat shock — and again, the chelator abolished this protection. This is notable because lifespan extension in worms usually comes from reduced protein synthesis; here, it came from increased synthesis. The resolution lies in translation fidelity, not volume: a separate ribosomal protein mutation that boosts accuracy without increasing synthesis rate already extends lifespan in yeast, flies, and worms. Zinc’s effect was systemic: it restored antioxidant defenses, chaperones (protein-folding helpers), energy metabolism, and damaged protein clearance to youthful levels. Without this coordination, the outcome could have been reversed — as shown in another study where increased translation without chaperone support cut damaged protein recovery after heat stress by nearly two-thirds, and worms with the same imbalance accumulated toxic protein aggregates faster, mimicking Huntington’s disease. In two human disease models — a polyglutamine model resembling Huntington’s and an amyloid model resembling Alzheimer’s — zinc significantly slowed the buildup of toxic protein clumps and muscle paralysis. Cleanup was targeted: the gene for capturing toxic cargo nearly doubled in expression, while the general cellular cleanup gene decreased. This contrasts with an earlier study from the same group, where zinc deficiency extended lifespan and supplementation shortened it. The difference lies in baseline conditions: the prior study varied zinc levels in healthy worms from deficiency to excess, whereas the current study only replenished an age-related loss within a non-toxic window. Experiments were conducted solely in C. elegans; the same dose window has not been tested in mammals, where zinc excess is already toxic. bioRxiv, October 9, 2026 🔗 Read original →
10
10
Schrödinger’s Bunsen agent handles 80% of computational drug discovery workload In an interview with BiopharmaTrend on October 10, Schrödinger’s chief scientific officer Robert Abel revealed that the Bunsen agent now performs approximately 80% of the company’s computational tasks on its cluster — calculations previously carried out by human computational chemists. Schrödinger plans a full commercial launch of Bunsen by the end of 2026. For 35 years, Schrödinger has sold software to pharmaceutical companies that physically simulates molecules at the atomic level to calculate how strongly a drug binds to its target protein. In 2016, Nimbus Therapeutics — co-founded by Schrödinger — sold a molecule designed using this technology to Gilead Sciences in a deal worth up to $1.2 billion, with the computations advancing it to a real drug candidate. Schrödinger released Bunsen in early access in late July. Among its first clients is pharmaceutical giant Bristol Myers Squibb: in August, BMS agreed to develop Bunsen for molecular calculations and integrate RetroSynth, a synthesis planning tool for selected molecules. Scientists describe tasks in plain language, Bunsen generates a computation plan for approval, and upon authorization, executes the full campaign without constant human oversight. Abel stated: “We recently found that about 80% of computational tasks on our cluster are now performed by Bunsen… Bunsen is doing serious work.” Inside Bunsen, a language model selects the appropriate validated method and its execution order, while the numerical result — such as binding energy — is produced by the method itself. “Numerical results come from these rigorously validated computational methods, not from the language model,” Abel said. This design avoids the chief risk of AI agents in science: plausible but physically incorrect numbers. Two years ago, in November 2024, Schrödinger CEO Ramy Farid called AI in drug discovery “nonsense,” arguing physics outperforms neural networks. At Bunsen’s July launch, he admitted: “I was extremely skeptical, honestly, and I can’t help but be glad I was wrong. This changes everything.” Agent-based systems at Schrödinger began development in late 2023, shortly after GPT-4’s release, and for 18 months they erred on simple tasks. Abel likens the moment to MYCIN, Stanford’s 1970s expert system for infection diagnosis: in a 1979 blind evaluation, physicians found MYCIN’s antibiotic recommendations acceptable in 65% of cases — higher than staff infectious disease doctors (42.5–62.5%). Yet MYCIN never entered clinical use due to legal liability for computer-based diagnoses and cumbersome data input. Bunsen differs: validation occurs at every step, and the simulation itself flags physically inconsistent results. “MYCIN had nothing like this except waiting for patient outcomes,” Abel noted. When asked whether Bunsen’s decisions are better — not just faster — Abel replied that comparing agent-assisted versus unassisted programs would be too costly an experiment. Instead, he cites two benchmarks: method accuracy and coverage — how many compounds are prioritized that would otherwise be missed. Farid in July described Bunsen’s licensing model as payment per volume of campaigns run. Abel in October clarified that formal terms remain unannounced, but the primary bottleneck for pharma companies is computational chemist time — typically juggling three to four projects simultaneously and unable to complete all necessary modeling; Bunsen frees this time. To handle growing workload ahead of full launch, Schrödinger is deploying Bunsen on Nvidia and Google Cloud infrastructure. This setup accelerates drug discovery across any therapeutic area: the agent takes on computational routine, while humans focus on question formulation and final verification. 🔗 Read original →
9
11
Stanford finds reversible way to pause liver cell metabolism without cold or low oxygen Liver transplant storage damage cut by 75% with new TorPause solution Stanford researchers have developed a method to reversibly pause liver cell metabolism without cold temperatures or reduced oxygen, using a novel solution called TorPause. In rat liver transplant models, storing organs at room temperature for five hours with TorPause reduced structural damage from 8 to 2 on a standardized scale and significantly lowered the risk of animal death. TorPause combines GSK212, an inhibitor of both mTOR and PI3K cell growth pathways, with AP39, a mitochondrial hydrogen sulfide donor that protects cells during blood flow restoration. The solution was added to the standard University of Wisconsin organ storage fluid and tested in transplantation. Control livers remained dark and congested, while those treated with TorPause retained normal color. In 14-day observation, all control and AP39-only rats died within the first day. Among rats receiving GSK212 or the full TorPause combination, one in four survived to day 14 in each group, with complete liver recovery. Risk analysis showed GSK212 reduced mortality risk by eightfold (p = 0.04). The approach mimics natural metabolic pauses seen in embryonic diapause and hibernation, targeting cellular control rather than external conditions. Previous attempts using inhaled hydrogen sulfide in mice (2005) failed in larger mammals due to concurrent oxygen deprivation, not the gas itself. Nakauchi’s team found that blocking only mTOR reduced cell growth by one-third, but dual inhibition of mTOR and PI3K produced a synergistic effect far beyond additive. GSK212 alone maintained metabolic pause in embryos for 8.5 days at normal oxygen levels, with 78% survival, while the prior hypoxic compound INK128 proved toxic under the same conditions. Combining GSK212 with AP39 addressed both metabolic suppression and reperfusion injury. Over 100,000 people in the U.S. await organ transplants, with about 17 dying daily due to donor shortages. The current storage window is limited by cold preservation, which slows but does not prevent ischemia-reperfusion injury — damage from halted and restored blood flow. Machine perfusion improves outcomes but is costly and unavailable at most clinics. Stanford has filed a patent for TorPause. Hiromitsu Nakauchi, known for work growing human organs in animals, holds stakes in unrelated biotech firms. The findings are detailed in a preprint . 🔗 Read original →
8
12
Enterobactin — a molecule gut bacteria use to scavenge iron — acts as a signal that disrupts two enzymes in roundworm neurons and extends lifespan Filipe Cabreiro’s lab at the University of Cologne systematically knocked out nearly 4,000 genes in Escherichia coli and tracked how each change affected Caenorhabditis elegans behavior. Worms exposed to bacteria overproducing enterobactin — an iron-chelating molecule — showed increased movement, better muscle preservation with age, and longer life. The preprint was posted on bioRxiv on 8 October 2026. In 2018, another group had shown enterobactin delivers iron to worm mitochondria to support larval growth; Cabreiro’s team hypothesized the same molecule might also regulate behavior, health, and aging in adult worms. In this screen, iron metabolism genes had the strongest behavioral impact: worms on bacteria lacking the fepD gene — which returns captured iron to the bacterium — moved significantly faster than normal. Without fepD, the bacterium rewires its metabolism and produces far more enterobactin to acquire iron. Knocking out enterobactin biosynthesis genes abolished the effect; adding its precursors restored it. Enterobactin is nature’s strongest known iron chelator, binding iron with an affinity constant of 10⁵² — 27 orders of magnitude stronger than EDTA, a synthetic metal chelator. To find the mechanism, researchers identified which proteins enterobactin binds. It bound most tightly to mitochondrial glutaryl-CoA dehydrogenase (GCDH). Modeling revealed the molecule sits in the same pocket where the electron carrier FAD normally resides, destabilizing the structure of two of its electron-transfer partners. In humans, mutations in this gene cause glutaric aciduria type 1, a disorder with movement impairments. The authors directly link their worm finding to this human condition: the same mitochondrial node is vulnerable both to human mutation and to bacterial enterobactin. Disrupting electron transfer raises reactive oxygen species (ROS) levels in neurons. This surge does not act as damage but as a signal: it triggers a protective program that restores cellular protein balance and extends animal lifespan. In worms, a similar “shake-up” had previously been induced by damaging Complex I or Complex IV in the electron transport chain — each activating incompatible protective programs. Enterobactin added a third, bacterial entry point. Vitamin C, as an antioxidant, blocked both the acceleration and lifespan extension; knocking out SOD-2 amplified both effects under enterobactin, while the prooxidant paraquat reproduced them alone. NMDA receptors — expected signal transducers given their overexpression in the same human disease — were blocked, contrary to expectation, which enhanced enterobactin’s effect, indicating the signal travels via another route. The true mediator turned out to be the PDFR-1 receptor — the same one previously known to regulate worm excitation and foraging. Without PDFR-1 and its neuropeptide partner, all enterobactin effects — movement, muscle health, longevity — disappeared. Cabreiro frames the finding: enterobactin is a byproduct of bacterial iron competition that accidentally hijacks an ancient neuronal pathway in the host, seizing control of it. The authors term such molecules “neuromanipulators” — bacterial compounds that tune host behavior for bacterial survival, incidentally altering host aging rates. 🔗 Read original →
10
13
ZNF865 identified as a molecular switch that reverses disc aging and pain The protein ZNF865, previously uncharacterized in the human genome, has been identified as a key regulator between healthy and aging intervertebral disc cells. Its deletion triggers cellular aging, DNA damage, and disc degeneration, while restoration reverses these processes. This first functional characterization of ZNF865 (also known as BLST) was published on October 9 in the journal Aging Cell by the tissue engineering lab at the University of Utah, which focuses on disc repair. Knocking out the gene in healthy human disc cells induces aging and DNA damage, whereas restoring it in aged disc cells from patients with back pain reverses both. In live rats, direct injection of a ZNF865-knockout construct into the disc under X-ray guidance caused degeneration and increased pain sensitivity within 5–8 weeks. Robbie Bowles leads the biomedical engineering lab at the University of Utah. Several years ago, his team screened for disc-engineering genes using CRISPR and discovered ZNF865 — a protein with no published function — initially used simply to grow disc tissue. Unexpected gene activity measurements revealed its involvement in DNA repair and cellular aging. “In short, it regulates cellular aging — which is critically important for aging and has applications in musculoskeletal diseases,” Bowles explains. ZNF865 is a zinc finger protein, a structural motif that binds DNA to activate or repress nearby genes. In humans and mice, its levels in disc cells decline with age and degeneration — a factor implicated in approximately 40% of back pain cases, one of the leading global causes of disability. When the researchers expressed ZNF865 in kidney, fat, and disc cells, all three cell types showed modulation of the same narrow set of pathways: cell division, DNA repair, and aging. Upon ZNF865 knockout in healthy disc cells, three aging markers increased 4.7- to 6.9-fold, with DNA damage rising three weeks later. Conversely, restoring ZNF865 in aged disc cells from back pain patients reduced aging and DNA damage, decreased nine out of ten SASP (senescence-associated secretory phenotype) inflammatory proteins typically secreted by senescent cells, and increased collagen production. DNA accessibility in these cells became nearly indistinguishable from healthy cells, with differences reduced by 94%. The final step involved in vivo testing: researchers injected a ZNF865-silencing construct into rat discs under X-ray control. After 5–8 weeks, animals exhibited heightened pain sensitivity, degeneration markers, and reduced disc height in one of two discs. Most rat disc degeneration models achieve this via needle puncture or enzyme injection; here, the phenotype was driven by a single gene knockout. The authors propose ZNF865 as a potential therapeutic target for aging and DNA damage across tissues, as it functions in all human cell types, and rare inherited mutations in it disrupt joints, muscles, skin, vision, and hearing. ZNF865 is the second zinc finger protein without known function identified in the past year as a master regulator of aging; in July, the same lab found ZNF512B to repair damaged DNA and suppress the same SASP profile via chromatin remodeling. Bowles is translating the discovery into therapy: “Our methods are primarily injections — easier for patients and a way to reduce opioid use.” His lab is preparing to test the same gene in conditions like Parkinson’s, where cellular aging damages neurons. 🔗 Read original →
9
14
Immune Cell Atlas of 2,609 People Finds Blood Marker of Death Comparable to Male Sex — Driven by Lifelong Herpes Virus, Age Has Little Influence October 9 in the journal Immunity, a team from Washington University in St. Louis, King’s College London, and several other institutes published findings after combining single-cell blood data from 2,609 people across four continents — totaling 12.4 million immune cells. They discovered that killer immune cells age differently among individuals of the same chronological age. To validate their protein-based immune aging score, they tested it on 48,620 participants from the UK Biobank over 17 years of follow-up. Previous human immune aging studies had poor cross-laboratory consistency, so the team compared eight independent cohorts and retained only changes reproduced in at least five. The most reliable signal was a long-known process now measured with greater precision: the thymus — the organ behind the breastbone that produces new T lymphocytes — weakens with age, reducing the output of fresh T cells in the blood. Built on this, their “immune clocks” predict a person’s age with an error of about eight years. The second discovery is largely independent of age. Among memory killer T cells (CD8 lymphocytes that destroy infected and cancerous cells), two groups exist — one uses the enzyme granzyme K, the other granzyme B. One of the lead authors, immunologist Maxim Artemov from the same university, noted that in 2023 his lab first observed this divergence in a single cohort, and by 2024 they had learned to measure thymic T-cell output via the protein CD38. In young people, the two groups are roughly equal, and age shifts this ratio only slightly: a 1.2-fold increase from ages 18 to 64, then a decline to 0.64 by age 97 — representing a separate axis of variation unrelated to aging. The balance toward granzyme B is sharply shifted by cytomegalovirus — a lifelong, usually asymptomatic herpes virus infecting most adults. In people with chronic cardiovascular disease and lupus, the skew was stronger even without the virus. This presents a pitfall for translating mouse data to humans. In old mice, granzyme K-positive T cells represent a terminally exhausted stage, a marker of tissue inflammatory aging: transferring such cells to young mice impaired memory, while blocking the enzyme improved it in old mice. In humans, however, granzyme K is carried by intermediate-stage cells, while the terminal, most inflammatory cell carries granzyme B. The human equivalent of “bad” mouse cells is not in blood but in tissues — for example, in tumors. The cause of this discrepancy remains unclear. Directly counting these cells requires expensive single-cell sequencing, impractical for large cohorts. Therefore, the team identified plasma proteins linked to the proportion of granzyme B-positive cells and trained a simple model on them. Applying it to 48,620 UK Biobank participants, they found that among 60–70-year-olds, the risk of death from any cause in the top quarter by this measure was 43% higher than in the bottom quarter — comparable to the sex difference in the same model: men had a 66% higher risk than women. The effect replicated in younger individuals independent of sex. These same individuals also had higher rates of sepsis, type 2 diabetes, gout, liver disease, and kidney failure — but not dementia or Parkinson’s disease. The map connects immune profile to mortality risk, but no drugs or protocols currently exist to correct the granzyme balance. Five co-authors, including Artemov, have filed a preliminary patent application for the protein test itself. 🔗 Read original →
8
15
Aging Is Not Random DNA Chaos — It’s a Choice of What Cells Protect Nathaniel David, cofounder of Unity Biotechnology, compared a long-lived tortoise and dogs to propose a testable hypothesis about transposons On October 10, Nathaniel David, cofounder of Unity Biotechnology — a biotech firm developing drugs against cellular aging — posted a thread on X comparing two recent findings: gene stability in Jonathan, a 194-year-old tortoise, and loss of control over mobile DNA segments in large dog breeds. From this comparison, he derived a unified principle of aging and a testable hypothesis about the sequence of events in dogs. Comparing mice and whales is meaningless: they differ in a million ways, and it’s unclear which matters for aging. Instead, David compares nearly identical animals with sharply different lifespans within a single species — dog breeds or Jonathan and his kin, who typically don’t live past 100. Jonathan’s epigenome — the pattern of chemical marks on DNA that turn genes on and off — showed that with age, these marks scatter chaotically across the genome everywhere except at promoters of mitochondrial genes, RNA processing genes, and DNA repair genes — where they remain sharp, as in a five-year-old hatchling. Jonathan also has extra copies of DNA repair genes and ten copies of the perforin gene — versus seven in another giant tortoise, Lonesome George. Perforin lets immune cells punch holes in target cells’ membranes; extra copies may enhance the removal of senescent and cancerous cells. In dogs, the pattern is mirrored. Analysis of methylation across breeds of different sizes revealed that large breeds — which live shorter lives than small ones — lose methylation fastest on transposons: DNA segments capable of copying themselves and inserting into new genome locations, especially the youngest ones. David synthesizes both facts into a thesis: Aging is not about avoiding disorder. It’s about choosing where to allow it. The tortoise protects mitochondrial and DNA repair genes; dogs first lose control over transposons. “Everything degrades. What matters is what you protect,” he writes. Epigenetic clocks — estimates of biological age based on methylation patterns — run faster in youth for dogs, not old age: a large breed appears epigenetically older than a small breed of the same age, even though damage accumulation should accelerate clocks later in life. David interprets this as an ongoing developmental program: “Aging is more like growth that never stops than like wear and tear.” This explains an old paradox: within a species, larger individuals live shorter lives; between species, the opposite usually holds. Within a species, extra size means extra growth on a fixed tissue repair budget; between species, evolution raises the budget alongside size — along with extra DNA repair and perforin gene copies in the tortoise. According to David, for humans, each year by which epigenetic age outpaces chronological age raises mortality risk by 2%; for dogs, it’s 15%. But dogs live roughly six times shorter than humans, so when scaled to fraction of lifespan, the effect is equivalent. He calls the dog study solid and the tortoise work a hypothesis: one animal versus four, and part of the tortoise paper’s genetic analysis, in his view, doesn’t support its conclusions. Together, they yield a testable prediction: if transposon derepression drives aging — rather than merely marking it — it should precede inflammation and cancer in dogs, especially in larger breeds. He invites the authors of the same dog project to test this. 🔗 Read original →
10
16
Terrence Tao posed a thought experiment: AI found a cancer drug that passed trials without a clear mechanism — would you take it? The debate split social media, and an oncologist reminded Tao that medicine has long treated patients with drugs whose mechanisms are not fully understood. On October 9, 2026, Terrence Tao delivered a lecture titled “Math 2.0” at Caltech, featuring a slide: AI discovers a cancer drug without an understandable mechanism. The next day, a screenshot of the slide garnered over 9,000 likes and 1.2 million views on X. Oncologist Vinay Prasad responded: medicine already uses drugs with incompletely understood mechanisms of action. Tao, a Fields Medalist — the highest honor in mathematics — expanded on an idea from his July lecture: mathematics is entering an era of proof abundance, where AI generates proofs faster than humans can absorb them. Previously, seeking solutions built understanding of the field; now, chasing answers alone severs that connection. In pure mathematics, this substitution is safe: Lean verifies proofs line by line without missing errors. Tao’s thought experiment shows that even such verification fails in the real world: AI selects a cocktail of substances, Lean confirms its mathematical model, the cocktail passes final third-phase human trials — yet the question remains: did it cure cancer, or merely exploit a weakness in the trial procedure, with no one understanding its mechanism? “Could an AI solution to this request be misaligned because it exploits a flaw in the trial procedure itself? Before injecting this cocktail into your blood, would you want to know that at least one human oncologist understands its mechanism?” Tao had raised the same risk in early September using the Navier–Stokes equations, which describe fluid motion: an AI solution found by bypassing human discovery deprives the field of new ideas born from the search process itself. On the cancer slide, the same error stands not for proof, but for patient health. Reviewer Andrew Carran posted the slide photo: if the drug works, a patient with stage IV cancer doesn’t care whether anyone understands its mechanism. User kenbwork agreed: we don’t need AI dosing incomprehensible drugs. Another critic replied sharply: the mathematician “is laying rhetorical groundwork for banning AI cancer drugs” and “will kill people.” Everyone responded to Carran’s summary — no one discussed the slide’s actual phrasing about exploiting a flaw in the trial procedure. Prasad — a hematologist-oncologist, professor at UC San Francisco, who twice led the FDA’s biologics unit in 2025–2026 and twice resigned after criticism — replied to Carran’s version. Six months earlier, he had established a single pivotal trial as standard, replacing the prior requirement of two. The mechanism of many cancer drugs remains incompletely understood: no general theory for doxorubicin, no one knows why sevoflurane gas turns off consciousness. “If AI creates a cancer drug whose mechanism nobody understands, but it passes a full randomized third-phase trial, no cancer patient on Earth would say ‘no, thank you.’ Today we accept far less evidence.” Prasad is medically correct, but Tao’s question remains unanswered: did the trial confirm cure, or merely the ability to evade the testing procedure? Tao proposes not a ban, but open mathematical models for interpretability and safety, promised soon. Whether medicine deems trial statistics sufficient — or demands an explained mechanism — will determine how quickly AI drugs reach patients who have nothing left to wait for. 🔗 Read original →
11
17
Birth weight and breastfeeding influence organ aging decades later, UK Biobank study shows A study of 44,800 UK Biobank participants, published in Aging Cell on 9 October, links early-life factors to the pace of organ aging across 19 body systems. Researchers built organ-specific “aging clocks” using levels of nearly 3,000 blood proteins, then correlated them with birth weight (available for 21,400 participants) and breastfeeding history (recorded for 29,700). Higher birth weight — adjusted for lifestyle and existing disease — was associated with slower aging in 11 of the 19 systems, strongest in the gut, oesophagus, and stomach. Notable effects also appeared in the immune system, kidneys, liver, salivary glands, thyroid and adrenal glands, skin, and muscles. Breastfeeding selectively slowed aging in the gut and adrenal glands but accelerated it in the thyroid, a finding the authors call unexpected, possibly due to unstable iodine and thyroid hormone levels in milk stressing the infant’s immature gland. When both factors were present, their combined effect exceeded a simple sum: for the gut, the joint impact was nearly twice as strong as birth weight alone. The researchers identified a partial mechanism for birth weight’s effect: “allostatic load” — the cumulative wear from chronic stress, measured via metabolic, cardiovascular, and inflammatory markers — explained up to 35% of the link with accelerated skin aging and 30% for adrenal glands, but far less for the gut and stomach, suggesting a more local process there. For breastfeeding, allostatic load explained none of the observed effects, pointing instead to early influences like milk composition and gut microbiota establishment. Both effects were stronger in women and those with higher socioeconomic status, indicating that later-life experiences shape how early advantages unfold. Participants self-reported birth weight and breastfeeding in mid-to-late life. Though such recall typically weakens true associations, nine of the eleven birth weight links remained significant even after adjusting for both factors, supporting the robustness of the findings. The study builds on organ-specific aging clocks first developed in small cohorts in 2023 and scaled to UK Biobank in 2025. A Scottish validation of the same clocks, published 1 October, found them less accurate than brain MRI and three other methods for predicting mortality. 🔗 Read original →
9
18
Loss of Lamin B1 Triggers Mitochondrial Failure in Aging Bone Stem Cells, Weakening Bones — Approved Drug Nalmefene Breaks the Chain In aging bone stem cells, researchers identified a complete cascade of failures — from loss of nuclear protein Lamin B1 to mitochondrial dysfunction — that weakens bones, and found an already-approved drug that breaks this chain. Scientists from Sun Yat-sen University in Shenzhen traced the mechanism in patient cells and mice, publishing their findings on October 8. They showed that age-related loss of Lamin B1 activates the gene SLC7A11, damages actin — the cell’s structural protein — through excess sulfur bonds, and halts mitochondrial division. Among approved drugs, nalmefene — used for opioid-induced constipation — blocks this link. Bone is constantly renewed: some cells break it down, while bone marrow stem cells build new bone. In aging people, breakdown outpaces formation, leading to senile osteoporosis, but why stem cells fail to build bone was unclear. The authors began with Lamin B1, a nuclear envelope protein whose loss is considered a hallmark of cellular aging. Normally, it “tethers” DNA regions to the nuclear envelope, keeping them silenced. When Lamin B1 disappears, DNA packaging weakens, and a “super-enhancer” — a cluster of regulatory elements — forms, sharply activating one gene. Among genes in these regions, only one showed abnormal activity in both aging and osteoporosis: SLC7A11, a pump that imports the amino acid cystine into the cell. Excess SLC7A11 floods the cell with more cystine than it can process: lacking sufficient NADPH reductase, cystine forms abnormal sulfur bonds in actin — a process discovered in 2023 in cancer cells and termed disulfideptosis; the original paper has already garnered nearly a thousand citations. Cancer cells require external glucose deficiency for this; aged bone stem cells do not: they poorly uptake glucose and produce less NADPH even in nutrient-rich conditions. Collapsed actin fails to retain the protein DRP1, which divides mitochondria: without division, damaged mitochondrial fragments are not cleared, mitochondria produce less energy, and the cell lacks the strength to become a bone-forming cell. To prove causality, the authors generated mice lacking Lamin B1 specifically in bone cells — these mice developed accelerated osteoporosis. Separately, in 18-month-old mice (mouse equivalent of old age), knocking out SLC7A11 prevented bone loss, as seen in normal old mice. In the decisive experiment, mice lacking Lamin B1 also had SLC7A11 knocked out — bone loss did not occur, confirming SLC7A11 acts downstream of Lamin B1. The same chain was confirmed in bone marrow from elderly patients, and genomic analysis linked LMNB1 variants to osteoporosis risk. Since Lamin B1, as a structural protein, is difficult to target with drugs, and SLC7A11 is a membrane pump with a known 3D structure, the researchers screened it against a library of approved drugs and identified nalmefene — a Japanese pharmaceutical from Shionogi that blocks intestinal opioid receptors to treat opioid-induced constipation. A 30-day treatment restored bone mass in osteoporotic mice and accelerated skull defect healing, without altering blood, liver, kidney, or heart markers. SLC7A11 also has a protective function — in cancer cells, it shields against ferroptosis, another form of cell death, and excessive inhibition may pose this risk. Therefore, the authors call nalmefene dosing a matter of fine-tuning, and the drug’s link to SLC7A11 a conclusion drawn from docking and simulation. California biologists have linked the waning efficacy of osteoporosis drugs to therapies that accelerate overall bone turnover rather than targeting the bone stem cell pool itself; nalmefene’s target is precisely there, and its safety is already established — albeit for a different indication. 🔗 Read original →
12
19
Muscle aging and early Alzheimer’s trigger the same inflammatory program in blood vessels and immune cells — two genes identified as potential common switches A team from Zhejiang University and Amsterdam University Medical Center compared gene activity in old and young muscle with data from human brains at early Alzheimer’s stage. Inflammatory gene sets matched in blood vessels and immune cells of both tissues, and a similar signal was found in the blood of living people. A computational model pointed to two genes whose virtual “switching off” consistently dampened inflammation in both tissues. The idea that weakening muscles and a fading brain are manifestations of one process has long centered on proteins muscles release into the blood, like irisin. This preprint from October 8 — a scientific article prior to journal publication — shifts the idea to the cellular level: which genes are active in muscle and brain. On the muscle tissue atlas — nearly 300,000 cells from young and elderly donors — inflammatory gene activity rose in 11 of 15 cell types in older individuals, and intercellular signaling increased by 77%. For the brain, they used the Allen Institute atlas — 1.1 million cell nuclei from 84 donors with a continuous severity scale based on autopsy, not a binary “healthy or sick” diagnosis. On the early stage of this scale, brain immune cells and vessels showed the same rise in inflammatory programs. As disease progressed further, brain cell signaling networks weakened: total strength dropped nearly 20%, and activity in 38 of 39 inflammatory pathways — groups of genes activated together — declined, which is why early Alzheimer’s was compared to muscle aging. The authors then focused on genes in vascular and immune cells — the only cell types with comparable roles in muscle and brain. Six of eight inflammatory pathways matched in vascular cells (109 shared genes), and four of eight in immune cells (51 genes). A similar stable cross-species inflammatory cell subgroup had been found before in another tissue: in mice, baboons, and humans, a pro-inflammatory subgroup of lung alveolar macrophages increased more than tenfold with age. In blood, the signal varied in strength: with physical frailty — weakness and slow gait — the same pathways were active in 30 of 36 “pathway–cell type” checks; with mild cognitive impairment, only one; with Alzheimer’s, five. In two independent blood donor groups, 23 of 30 checks confirmed the same direction. In a computational model of gene regulatory links, the authors virtually switched off 18 candidate genes one by one, comparing effects in both tissues for 13 of them. Only ETS2 and BHLHE40 showed stable, predictable weakening of inflammatory programs across all donors, passing all model stability checks. The authors call this pair a hypothesis for lab testing: the effect did not survive statistical correction, and muscle and brain samples came from different people — so the “muscle → brain” link remains to be proven experimentally. ETS2 has another history: in June 2024, the Francis Crick Institute showed in Nature that its overactivity recreates inflammation in Crohn’s disease and ulcerative colitis, and MEK inhibitors blocking its activation suppress inflammation in cell experiments. BHLHE40 is known otherwise: in T-cells it sets the balance between inflammatory and anti-inflammatory signals, and in macrophages it governs their proliferation. This preprint translates the idea of muscle and brain aging into a list of matching genes and names molecules whose connection might be tested for disruption. 🔗 Read original →
15
20
Space Biostasis Summit Announces 30 Speakers: Cryobiologist Greg Fahy, Hibernation Researcher Sinisa Hrvatin, and Two ARPA-H Managers Focus on Controlled Metabolic Pause for Space On October 9, the nonprofit Space Biostasis Coalition announced the speaker list for its upcoming summit, confirming 30 presenters including cryobiologist Greg Fahy, hibernation researcher Sinisa Hrvatin, and two ARPA-H managers. The summit website confirms the program: the conference will take place February 9–11, 2027, at Space Center Houston, adjacent to NASA’s Johnson Space Center where astronauts are trained. The theme centers on engineering pathways to a controlled metabolic pause in humans for deep-space travel. Over six months of spaceflight, the body deteriorates predictably: according to coalition calculations, bones lose about 10% of density, muscles lose 15% of mass, the heart ages as if an extra 10 years have passed, and NASA data shows kidney stone risk increases sevenfold. A one-way trip to Mars takes seven to nine months: each crew day adds mass and cost to the spacecraft. NASA has pursued solutions since 2013, when it proposed a crew transport module with induced hibernation, and in 2024 supported the STASH experiment on the ISS — testing whether such hibernation protects animals from muscle and bone loss in microgravity. The European Space Agency calculated that crew hibernation could reduce a Mars-bound spacecraft’s size by one-third. Biostasis is an umbrella term for controlled, reversible metabolic arrest. The coalition’s website breaks it down by methodological maturity: hypothermia — routine in cardiac surgery and resuscitation — maintains pause for minutes; synthetic torpor — experimental activation of brain neurons in mice and hamsters — extends it to days; cryostasis at near-zero temperatures is designed for weeks for tissues and organs; vitrification — replacing ice with a glass-like state without cellular destruction — holds pause for millennia in theory but has only been proven for individual animal tissues, not whole organisms. For over a decade, NASA, ESA, cryobiologists, hibernation biologists, and federal grantmakers pursued this agenda separately — the summit is the first to bring them together. The speaker list includes Greg Fahy of 21st Century Medicine, developer of the M22 solution, which in the 2000s set an unmatched record: a vitrified, rewarmed, and transplanted rabbit kidney sustained the animal’s life. Also featured is Sinisa Hrvatin of the Whitehead Institute at MIT: his lab identified hypothalamic neurons triggering torpor in mice, and in a Nature Aging study, his team showed that repeatable artificial torpor slowed epigenetic aging in mouse blood by nearly 40%. ARPA-H, the U.S. Health Department’s agency for high-risk medical programs, has no dedicated space hibernation program: at the summit it is represented by two managers — Gloria Elliott leads an $87 million program for storing cellular products without deep freezing, and a parallel effort for donor organs; Jean Eber leads the FRONT program, aiming to replace aging brain tissue via transplants. One community works on both earthly organ storage and spaceflight — via whole-human metabolic pause.… 🔗 Read original →
16